BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 33548517)

  • 1. Indirect Treatment Comparison of Biologics in Chronic Rhinosinusitis with Nasal Polyps.
    Peters AT; Han JK; Hellings P; Heffler E; Gevaert P; Bachert C; Xu Y; Chuang CC; Neupane B; Msihid J; Mannent LP; Guyot P; Kamat S
    J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2461-2471.e5. PubMed ID: 33548517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologics for chronic rhinosinusitis.
    Chong LY; Piromchai P; Sharp S; Snidvongs K; Webster KE; Philpott C; Hopkins C; Burton MJ
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013513. PubMed ID: 33710614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologics for chronic rhinosinusitis.
    Chong LY; Piromchai P; Sharp S; Snidvongs K; Philpott C; Hopkins C; Burton MJ
    Cochrane Database Syst Rev; 2020 Feb; 2(2):CD013513. PubMed ID: 32102112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Different Biologics for Treating Chronic Rhinosinusitis With Nasal Polyps: A Network Analysis.
    Cai S; Xu S; Lou H; Zhang L
    J Allergy Clin Immunol Pract; 2022 Jul; 10(7):1876-1886.e7. PubMed ID: 35272073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Which Is the Best Biologic for Nasal Polyps: Dupilumab, Omalizumab, or Mepolizumab? A Network Meta-Analysis.
    Wu Q; Zhang Y; Kong W; Wang X; Yuan L; Zheng R; Qiu H; Huang X; Yang Q
    Int Arch Allergy Immunol; 2022; 183(3):279-288. PubMed ID: 34607329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defining the Efficacy of Omalizumab in Nasal Polyposis: A POLYP 1 and POLYP 2 Subgroup Analysis.
    Damask C; Chen M; Holweg CTJ; Yoo B; Millette LA; Franzese C
    Am J Rhinol Allergy; 2022 Jan; 36(1):135-141. PubMed ID: 34382434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Dupilumab Versus Omalizumab in Chronic Rhinosinusitis With Nasal Polyps and Asthma: EVEREST Trial Design.
    De Prado Gomez PharmD MSc L; Khan Mbbs Mph AH; Peters Md AT; Bachert Md PhD C; Wagenmann Md M; Heffler Md PhD E; Hopkins BMBCh C; Hellings Md PhD PW; Zhang PhD M; Xing PhD J; Rowe Md P; Jacob-Nara Md Mph DHSc JA
    Am J Rhinol Allergy; 2022 Nov; 36(6):788-795. PubMed ID: 35837739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of dupilumab in patients with a history of prior sinus surgery for chronic rhinosinusitis with nasal polyps.
    Hopkins C; Wagenmann M; Bachert C; Desrosiers M; Han JK; Hellings PW; Lee SE; Msihid J; Radwan A; Rowe P; Amin N; Deniz Y; Ortiz B; Mannent LP; Rout R
    Int Forum Allergy Rhinol; 2021 Jul; 11(7):1087-1101. PubMed ID: 33611847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
    Bachert C; Han JK; Desrosiers M; Hellings PW; Amin N; Lee SE; Mullol J; Greos LS; Bosso JV; Laidlaw TM; Cervin AU; Maspero JF; Hopkins C; Olze H; Canonica GW; Paggiaro P; Cho SH; Fokkens WJ; Fujieda S; Zhang M; Lu X; Fan C; Draikiwicz S; Kamat SA; Khan A; Pirozzi G; Patel N; Graham NMH; Ruddy M; Staudinger H; Weinreich D; Stahl N; Yancopoulos GD; Mannent LP
    Lancet; 2019 Nov; 394(10209):1638-1650. PubMed ID: 31543428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials.
    Gevaert P; Omachi TA; Corren J; Mullol J; Han J; Lee SE; Kaufman D; Ligueros-Saylan M; Howard M; Zhu R; Owen R; Wong K; Islam L; Bachert C
    J Allergy Clin Immunol; 2020 Sep; 146(3):595-605. PubMed ID: 32524991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative analysis of endoscopic sinus surgery versus biologics for treatment of chronic rhinosinusitis with nasal polyposis.
    Miglani A; Soler ZM; Smith TL; Mace JC; Schlosser RJ
    Int Forum Allergy Rhinol; 2023 Feb; 13(2):116-128. PubMed ID: 35980852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of type 2 inflammatory signatures and efficacy of dupilumab in patients with chronic rhinosinusitis with nasal polyps from two phase 3 clinical trials: SINUS-24 and SINUS-52.
    Bachert C; Khan AH; Lee SE; Hopkins C; Peters AT; Fokkens W; Praestgaard A; Radwan A; Nash S; Jacob-Nara JA; Deniz Y; Rowe PJ
    Int Forum Allergy Rhinol; 2024 Mar; 14(3):668-678. PubMed ID: 37548085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olfactory Outcomes With Dupilumab in Chronic Rhinosinusitis With Nasal Polyps.
    Mullol J; Bachert C; Amin N; Desrosiers M; Hellings PW; Han JK; Jankowski R; Vodicka J; Gevaert P; Daizadeh N; Khan AH; Kamat S; Patel N; Graham NMH; Ruddy M; Staudinger H; Mannent LP
    J Allergy Clin Immunol Pract; 2022 Apr; 10(4):1086-1095.e5. PubMed ID: 34628065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Dupilumab on Sinonasal Symptoms and Outcomes in Severe Chronic Rhinosinusitis With Nasal Polyps.
    Hopkins C; Mullol J; Khan AH; Lee SE; Wagenmann M; Hellings P; Fokkens W; Msihid J; Nair R; Kamat S; Nash S; Radwan A; Jacob-Nara JA; Deniz Y; Rowe PJ
    Otolaryngol Head Neck Surg; 2024 Apr; 170(4):1173-1182. PubMed ID: 38156522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effect of Dupilumab on Intractable Chronic Rhinosinusitis with Nasal Polyps in Japan.
    Fujieda S; Matsune S; Takeno S; Asako M; Takeuchi M; Fujita H; Takahashi Y; Amin N; Deniz Y; Rowe P; Mannent L
    Laryngoscope; 2021 Jun; 131(6):E1770-E1777. PubMed ID: 33226139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS-52 is unaffected by eosinophilic status.
    Fujieda S; Matsune S; Takeno S; Ohta N; Asako M; Bachert C; Inoue T; Takahashi Y; Fujita H; Deniz Y; Rowe P; Ortiz B; Li Y; Mannent LP
    Allergy; 2022 Jan; 77(1):186-196. PubMed ID: 33993501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dupilumab efficacy in patients with chronic rhinosinusitis with nasal polyps with and without allergic rhinitis.
    Peters AT; Wagenmann M; Bernstein JA; Khan AH; Nash S; Jacob-Nara JA; Siddiqui S; Rowe PJ; Deniz Y
    Allergy Asthma Proc; 2023 Jul; 44(4):265-274. PubMed ID: 37480206
    [No Abstract]   [Full Text] [Related]  

  • 18. Dupilumab in CRSwNP: Responder Analysis Using Clinically Meaningful Efficacy Outcome Thresholds.
    Chuang CC; Guillemin I; Bachert C; Lee SE; Hellings PW; Fokkens WJ; Duverger N; Fan C; Daizadeh N; Amin N; Mannent LP; Khan AH; Kamat S
    Laryngoscope; 2022 Feb; 132(2):259-264. PubMed ID: 34817082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP.
    Desrosiers M; Mannent LP; Amin N; Canonica GW; Hellings PW; Gevaert P; Mullol J; Lee SE; Fujieda S; Han JK; Hopkins C; Fokkens W; Jankowski R; Cho SH; Mao X; Zhang M; Rice MS; Khan AH; Kamat S; Patel N; Graham NMH; Ruddy M; Bachert C
    Rhinology; 2021 Jun; 59(3):301-311. PubMed ID: 33847325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement in Smell Using Monoclonal Antibodies Among Patients With Chronic Rhinosinusitis With Nasal Polyps: A Systematic Review.
    Barroso B; Valverde-Monge M; Betancor D; Gómez-López A; Villalobos-Vilda C; González-Cano B; Sastre J
    J Investig Allergol Clin Immunol; 2023 Dec; 33(6):419-430. PubMed ID: 37669083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.